Robert W. Baird Downgrades Arcellx (NASDAQ:ACLX) to Hold

Arcellx (NASDAQ:ACLX) was downgraded by research analysts at Robert W. Baird from an “outperform” rating to a “hold” rating in a research report issued to clients and investors on Monday, MarketBeat reports. They presently have a $115.00 price target on the stock, up from their previous price target of $106.00. Robert W. Baird’s price objective would suggest a potential upside of 1.13% from the stock’s previous close.

A number of other equities analysts have also commented on the stock. Evercore set a $115.00 target price on shares of Arcellx in a research report on Monday. Wells Fargo & Company cut Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price objective on the stock. in a research note on Monday. Leerink Partners restated a “market perform” rating and set a $115.00 price objective on shares of Arcellx in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcellx in a report on Wednesday, January 21st. Finally, Guggenheim restated a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Two equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Arcellx presently has a consensus rating of “Hold” and an average target price of $111.64.

Arcellx Price Performance

ACLX stock opened at $113.71 on Monday. Arcellx has a 12 month low of $47.86 and a 12 month high of $114.26. The firm’s 50-day moving average is $68.84 and its 200 day moving average is $75.38. The company has a market capitalization of $6.57 billion, a PE ratio of -28.93 and a beta of 0.36.

Insider Transactions at Arcellx

In other Arcellx news, insider Christopher Heery sold 5,882 shares of the stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total transaction of $402,975.82. Following the sale, the insider owned 23,749 shares of the company’s stock, valued at approximately $1,627,043.99. This trade represents a 19.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 19,450 shares of company stock worth $1,283,477. 8.35% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arcellx

Hedge funds have recently made changes to their positions in the stock. MAI Capital Management purchased a new stake in shares of Arcellx during the third quarter worth about $26,000. CWM LLC raised its position in shares of Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock valued at $28,000 after purchasing an additional 251 shares during the last quarter. State of Wyoming acquired a new stake in Arcellx in the 2nd quarter worth approximately $28,000. Ramirez Asset Management Inc. purchased a new stake in Arcellx during the 3rd quarter worth approximately $41,000. Finally, Abich Financial Wealth Management LLC acquired a new position in Arcellx during the 3rd quarter valued at approximately $62,000. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Arcellx

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for $115.00 per share in cash plus one contingent value right worth $5.00 if milestones are met, implying up to ~$7.8 billion — a takeover premium that drove a large rally. Gilead acquisition release
• Positive Sentiment: Market reaction: the deal triggered a premarket surge (roughly 75–80% intraday move at announcement) and sharply elevated trading volumes as the market re‑priced ACLX to reflect the cash consideration. Reuters coverage
• Neutral Sentiment: HC Wainwright updated FY2030 EPS expectations materially (analyst projects $4.95/sh) but kept a “Neutral” rating and $115 price objective — effectively aligned with the deal price and not implying incremental upside beyond the offer. MarketBeat report
• Negative Sentiment: Multiple brokerages downgraded ACLX to “hold”/”equal weight” (Truist, Baird, Canaccord, Needham, Wells Fargo, Citigroup), signaling limited upside above the deal price and reducing buy‑side conviction. Example coverage: Truist/Benzinga. Benzinga downgrades roundup
• Negative Sentiment: Several law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Monteverde) announced investigations into whether the $115 + $5 CVR consideration is fair — potential litigation could seek a higher price, delay closing or increase transaction risk/uncertainty. KSF investor alert

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.